Jazz Pharmaceuticals, Inc. vs Abbvie Inc.
JAZZ vs ABBV — side-by-side comparison from reported financials. JAZZ leads 6, ABBV leads 4 of 10 comparable metrics.
Jazz Pharmaceuticals, Inc.
JAZZ · Healthcare
$218.42-1.81%Mixed
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | JAZZ | ABBV |
|---|---|---|
| Price | $218.42 | $276.43 |
| Market cap | $14.2B | $488B |
| Revenue (TTM) | $4.60B | $64.4B |
| Revenue growth | +5.3% | +1.8% |
| Net margin | 20.4% | 9.8% |
| Free cash flow | $1.59B | $18.2B |
| Net cash (debt) | ($2.94B) | ($56.2B) |
| 1-year price return | +58.1% | +19.8% |
| P/E | 15.1 | 77.4 |
| P/E vs own history (cheap-side %) | 90% | 23% |
| Dividend yield | — | 2.45% |
| Return on equity | 21% | 96% |
| Altman Z-score | 2.13 | 2.33 |
| CV checks passed | 9 of 10 | 9 of 10 |
| Employees | 2,890 | 57,000 |
Full résumé-style profiles: JAZZ CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.